Adrenaline 1:1000
Phase 3Small molecule
Adrenaline 1:1000 is one of 44 small molecule programs targeting ART. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
43
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
91 competitors in ART
#DrugCompanyPhaseTrials
1Belamaf
GSKPhase 3
Venclexta
AbbViePhase 3
Rituxan
RochePhase 3
Treanda
AAzurity Pharmaceuticals
Phase 3
Brukinsa
BBeOne Medicines
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Attruby
NNavire Pharma Inc., a BridgeBio company
Phase 3
Cysteine Hydrochloride
NovartisPhase 2
Noradrenaline
IInstitute of Liver and Biliary Sciences, India
Phase 3
Vyvgart
ArgenxPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Adrenaline 1:1000. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- TThe University of Hong Kong